Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab and Trastuzumab in HER2+ Gastric Cancer
NCT05975749Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Jan 2023
- Primary completion
- Jan 2026
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of serplulimab, trastuzumab in gastric cancer (GC), sponsored by Fudan University. Started Jan 2023; status: recruiting.
02
Drugs
serplulimabtrastuzumab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT05975749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05975749.